Is Bicycle Therapeutics plc (BCYC) a Buy, Sell, or Hold?
Bicycle Therapeutics plc
NASDAQ:BCYC
$4.22 USD
$0.01 (0.24%)
- Volume
- 223.28K
- Average Volume
- 454.23K
- Market Capitalization
- $292.84M
- P/E Ratio
- -1.34
- Dividend Yield
- 0.00%
- Price Target
- $12.00
- Year High
- $9.18
- Year Low
- $3.92
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $12.66
| Source | Headline |
|---|---|
|
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of initial data from the randomized Phase 2 trial (Duravelo-2) evaluating zelenectide pevedotin (zelenectide) in previously untreated patients with metastatic urothelial cancer (mUC), demonstrating encouraging response rates and a. businesswire.com - 2026-05-21 17:00:00 |
|
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended March 31, 2026, and provided recent corporate updates. “The data we reported in the first quarter continues to provide further validation of the potential of our Bicycle technology to deliver oncology th. businesswire.com - 2026-04-30 07:00:00 |
|
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster presentations across five abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29–June 2 in Chicago. Presentation Details: Title: Interim analysis results from. businesswire.com - 2026-04-21 10:31:00 |
|
Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updates from its EphA2 pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026. “EphA2 is a potentially high value target that is widely expressed in cancer and has been considered undruggable following the failure of mu. businesswire.com - 2026-04-20 07:00:00 |
|
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade
The mean of analysts' price targets for Bicycle Therapeutics (BCYC) points to a 137.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 2026-04-16 10:55:27 |
